We all suffer if derivatives are treated like drugs

Regulators are clamping down on complexity, but risk harming innovation

David Rowe

I have written several times in the past about the role and potential dangers of complexity. Recent years have seen it become one of the animating themes in the prudential regulation of derivatives. Early last year, Avinash Persaud offered an informed and well-balanced discussion of the issue in the annual Financial Stability Review from the Banque de France.

Persaud points out that too much of the public discussion of capital markets regulation reflects little or no appreciation of the social b

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: